Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date

Reuters04-02

Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date

Unicycive highlighted oxylanthanum carbonate (OLC) as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.
FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.
Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.
Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.
Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624780548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624780548","market":"nz","top_or_hot":-1,"title":"Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Unicycive highlighted oxylanthanum carbonate (OLC) as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.\n        </li>\n<li>\n          FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.\n        </li>\n<li>\n          Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.\n        </li>\n<li>\n          Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.\n        </li>\n<li>\n          Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-02 01:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Unicycive highlighted oxylanthanum carbonate (OLC) as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.\n        </li>\n<li>\n          FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.\n        </li>\n<li>\n          Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.\n        </li>\n<li>\n          Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.\n        </li>\n<li>\n          Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UNCY","symbol_name":"Unicycive Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2n6HDD:1","article_id":"2624780548","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624780548","pubTimestamp":1775063054,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Unicycive highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. pu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UNCY":"Unicycive Therapeutics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Unicycive在6月29日PDUFA日期之前发布公司演示文稿，重点介绍OLC NDA审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNCY":0.9},"content_text":"Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date\n    \n\n\n          Unicycive highlighted oxylanthanum carbonate (OLC) as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.\n        \n\n          FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.\n        \n\n          Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.\n        \n\n          Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.\n        \n\n          Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624780548","isCrawlerRequest":true}